NCT07030907View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 16, 2025

Primary Completion Date

May 15, 2028

Study Completion Date

May 15, 2030

Conditions
Ovarian Cancer RecurrentOvarian CancerPlatinum Resistant Ovarian Cancer
Interventions
BIOLOGICAL

OPB-101

An autologous mesothelin (MSLN) CAR T cell therapy with antigen-dependent expression of OUTSMART designed IL-2 cytokine

Trial Locations (3)

14203

RECRUITING

Roswell Park, Buffalo

55455

RECRUITING

University of Minnesota, Minneapolis

77030

NOT_YET_RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Outpace Bio, Inc.
All Listed Sponsors
lead

Outpace Bio, Inc.

INDUSTRY

NCT07030907 - A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer | Biotech Hunter | Biotech Hunter